TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nova Biomedical advised customers to remove affected Gen 2.0 StatStrip Glucose Hospital Meter Systems from use or sale while a software update is developed. The FDA identifies the action as its most serious type of device recall; the reported problem can leave an old patient or quality-control ID on the screen and cause results to be assigned incorrectly. As of October 5, the company reported one serious injury and no deaths.
Nova Biomedical has advised customers to remove affected Gen 2.0 StatStrip Glucose Hospital Meter Systems from use or sale while the company develops a software update, after reports that an earlier patient or quality-control ID can remain on the meter screen during barcode scanning. The FDA identifies the action as its most serious type of recall, warning that a result assigned to the wrong medical record could affect treatment decisions.
The FDA notice says the removal applies to the Gen 2.0 model of the StatStrip Glucose Hospital Monitoring System. It does not apply to earlier versions, including the Gen 1.86 model. The notice also lists the StatStrip Glucose Hospital Meter System, model number 636850, and Glucose Hospital Meter System Multipack, model number 667390, as affected products.
Nova reported that customers had encountered cases in which previous information remained on the meter display after a patient ID or quality-control barcode was scanned. If that information is accepted, a glucose result could be linked to the wrong patient’s medical record or to an incorrect QC ID. Nova said the issue affects Gen 2.0 meters running all firmware versions but does not affect the analytical performance of glucose measurements themselves.
The company’s letters, initially sent July 31 and updated October 5, set out interim safeguards. Facilities using electronic medical records with admission, discharge and transfer data should check that “Validate Patient ID’s” is enabled in NovaNet. Nova also recommended setting the meter to log operators out after each test. Staff are instructed to check the displayed patient information after scanning and again when the result appears, and to report any result assigned to the wrong patient promptly.
Patient Identification and Treatment Risk
The concern is not that the meter necessarily produces an inaccurate glucose measurement; Nova says the analytical performance is unaffected. The risk is that an otherwise valid result could be associated with the wrong patient or record, potentially leading clinicians to act on information that does not belong to the person being treated.
The FDA notice says consequences could include delayed or unnecessary treatment, including inappropriate insulin administration, or failure to treat the intended patient. The severity depends on the patient’s actual glucose level and clinical condition. The agency identifies critically ill patients and infants as at greater risk, in part because infants may be unable to communicate symptoms of low blood sugar.
Hospitals may need to remove affected meters where alternatives are available, adjust workflows, and carefully check records while the software correction is pending. For facilities without an alternative device, the FDA relays Nova’s advice to continue using the listed safeguards until the update becomes available.
hospital point of care glucose meter with barcode patient ID scanning
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Which StatStrip Models Are Affected
The StatStrip device is a hand-held, battery-powered instrument that measures glucose in whole blood or a quality-control solution using Nova Biomedical test strips. It also stores test results and related information about patients, samples, operators, reagents and the meter. That recordkeeping role makes correct identity matching central to the issue described in the recall.
The FDA says Nova’s initial customer letter went out on July 31, followed by an updated letter on October 5. The action is limited to the newer Gen 2.0 system; the earlier Gen 1.86 model is explicitly excluded. Nova also put a shipment hold on new Gen 2.0 systems while corrective actions are being developed and validated.
As of October 5, Nova had reported one serious injury and no deaths associated with the issue. The FDA classification reflects the potential for serious harm if affected devices continue to be used without addressing the risk; it does not mean every meter or every test has caused an error.
“The issue affects StatStrip Glucose Hospital Meter Systems (Gen 2.0) operating on all versions of firmware and does not impact the analytical performance of glucose measurements.”
— Nova Biomedical, as quoted in the FDA recall notice
hospital blood glucose monitoring system with electronic medical record connectivity
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Open Questions on the Software Fix
The FDA notice says verification and validation of a software update were underway, and Nova intended a phased rollout in November 2026. The notice does not provide a final release date, say how long the rollout will take, or specify when each affected facility will receive the update. The schedule is described as Nova’s intention, not as a completed or guaranteed release.
The available information also does not detail the circumstances of the one serious injury reported by Nova, identify the affected patient or facility, or state whether the injury resulted from a particular treatment decision. The notice gives no total number of affected meters or customer reports. It is also not clear how many facilities have suitable alternative devices or how many will need to continue using the meters under the interim safeguards.
hospital glucose meter quality control solution and test strips
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Facilities Await Validated Update
Nova said it was working to verify and validate a software update intended to address the issue, alongside other changes it described as non-safety-related improvements. The planned next milestone in the FDA notice is a phased rollout in November 2026. Until an update is available, facilities should follow the company’s customer instructions and the FDA’s recommendations for their circumstances.
Hospitals should identify whether their systems are Gen 2.0, determine whether an alternative meter is available, and check that the recommended NovaNet settings are in place where applicable. Staff should verify patient identity both after scanning and when results display. If a result has been assigned to the wrong record, the FDA notice says facilities should notify the administrator and treating clinical team, and flag or remove the erroneous entry under their established medical-record correction procedures.
Customers in the United States with questions, quality concerns or adverse reactions are directed to contact Nova Biomedical. The notice does not include the full contact details in the provided material. Further updates are expected as the software correction is validated and the company begins its planned rollout.
Key Questions
Which glucose meters are covered by this removal?
The action covers the Gen 2.0 StatStrip Glucose Hospital Meter System, including the product and multipack models listed in the FDA notice. It does not apply to the earlier Gen 1.86 model.
Why did Nova recommend removing the meters?
Customers reported that an earlier patient or quality-control ID could remain on the screen after a barcode scan. If accepted, the meter could associate a result with the wrong patient record or QC ID.
Does the issue affect glucose measurement accuracy?
Nova told the FDA that the issue affects patient or QC identification and does not impact the analytical performance of glucose measurements. The risk is that a result may be attributed to the wrong person or record.
What should a facility do if it has no alternative meter?
The FDA notice relays Nova’s advice to continue using the affected device only while following interim safeguards. These include checking the patient ID after scanning and again when the result appears, and using the recommended NovaNet settings where applicable.
When is the software update expected?
Nova intended to begin a phased rollout in November 2026, after verification and validation. The notice does not give a firm release date for individual facilities or a completion date for the rollout.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
